Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
Clinical trial NCT05493501 · TERMINATED
Trial details
- NCT number
- NCT05493501
- Sponsor
- EQRx International, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-14
- Primary completion
- 2023-08-31
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.